The US Food and Drug Administration (FDA) has announced the launch of a new pilot programme. This programme aims to accelerate the review process for generic drugs. Companies research, develop, and manufacture these drugs entirely within the United States. Membership Required You must be a member to access this content.View Membership LevelsAlready a member? Log...